Montmed announced the launch of the SiteSmart® GLP-1 Pack, a pen needle format specifically designed for patients using once-weekly GLP-1 therapies. Developed in response to the rapid growth of medications such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®, the new 12-pack format is clinically aligned with the product monographs of leading GLP-1 medications on injection site rotation, providing a practical solution that better reflects weekly treatment schedules.
The SiteSmart GLP-1 Pack extends the reach of Montmed’s patented SiteSmart® injection site rotation platform into the rapidly growing GLP-1 category. Designed to align with weekly treatment regimens, the product combines proprietary patient-support tools with a practical packaging format tailored to the needs of patients, pharmacies, and healthcare providers.
SiteSmart remains the only pen needle platform supported by evidence from a randomized controlled trial demonstrating improved injection site rotation practices. Compatible with leading GLP-1 pen devices including the newly approved biosimilars and supported by broad reimbursement coverage across Canada, the launch further expands the SiteSmart platform into one of the fastest-growing segments of injectable therapies.
